25 Years of Proton Pump Inhibitors: A Comprehensive Review

Overview

Journal Gut Liver

Specialty Gastroenterology

Date 2016 Nov 15

PMID 27840364

Citations 195

Authors

Daniel S Strand

Daejin Kim

David A Peura

Affiliations

Soon will be listed here.

Abstract

Proton pump inhibitors (PPIs) were clinically introduced more than 25 years ago and have since proven to be invaluable, safe, and effective agents for the management of a variety of acid-related disorders. Although all members in this class act in a similar fashion, inhibiting active parietal cell acid secretion, there are slight differences among PPIs relating to their pharmacokinetic properties, metabolism, and Food and Drug Administration (FDA)-approved clinical indications. Nevertheless, each is effective in managing gastroesophageal reflux disease and uncomplicated or complicated peptic ulcer disease. Despite their overall efficacy, PPIs do have some limitations related to their short plasma half-lives and requirement for meal-associated dosing, which can lead to breakthrough symptoms in some individuals, especially at night. Longer-acting PPIs and technology to prolong conventional PPI activity have been developed to specifically address these limitations and may improve clinical outcomes.

Citing Articles

Anti-inflammatory effects of Esomeprazole in septic lung injury by mediating endoplasmic reticulum stress.

Wang P, Li H, Wu W J Bioenerg Biomembr. 2025; .

PMID: 40072652 DOI: 10.1007/s10863-025-10055-0.

Association between polymorphism and proton pump inhibitors adverse drug reactions: a narrative review.

Ibrahim A, Yusuff K, Awaisu A, Elewa H Front Pharmacol. 2025; 16:1523399.

PMID: 40070570 PMC: 11894441. DOI: 10.3389/fphar.2025.1523399.

Why think twice before prescribing proton pump inhibitors.

Lemmens A, Huysentruyt K, Vandenplas Y Eur J Pediatr. 2025; 184(3):227.

PMID: 40042553 DOI: 10.1007/s00431-025-06058-z.

Neurological Manifestations Associated With Hypomagnesemia Due to Proton-Pump Inhibitors: A Case Series.

James L, Rajan G, Devarajan D, Mohan A Cureus. 2025; 17(1):e78229.

PMID: 40027002 PMC: 11871551. DOI: 10.7759/cureus.78229.

Acid-Neutralizing Omeprazole Formulation for Rapid Release and Absorption.

Ramesh S, Zvonicek V, Pecek D, Pislova M, Beranek J, Hofmann J Pharmaceutics. 2025; 17(2).

PMID: 40006528 PMC: 11859824. DOI: 10.3390/pharmaceutics17020161.

References

Esplugues J, Marti-Cabrera M, Ponce J . [Safety of proton pump inhibitors]. Med Clin (Barc). 2007; 127(20):790-5. DOI: 10.1157/13095825. View

Koch M, Dezi A, Ferrario F, Capurso I . Prevention of nonsteroidal anti-inflammatory drug-induced gastrointestinal mucosal injury. A meta-analysis of randomized controlled clinical trials. Arch Intern Med. 1996; 156(20):2321-32. View

Ngamruengphong S, Leontiadis G, Radhi S, Dentino A, Nugent K . Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Am J Gastroenterol. 2011; 106(7):1209-18. DOI: 10.1038/ajg.2011.113. View

Prakash A, Faulds D . Rabeprazole. Drugs. 1998; 55(2):261-7; discussion 268. DOI: 10.2165/00003495-199855020-00009. View

Thomson A, Cohen P, Ficheux H, Fiorentini P, Domagala F, Homerin M . Comparison of the effects of fasting morning, fasting evening and fed bedtime administration of tenatoprazole on intragastric pH in healthy volunteers: a randomized three-way crossover study. Aliment Pharmacol Ther. 2006; 23(8):1179-87. DOI: 10.1111/j.1365-2036.2006.02781.x. View

Hagymasi K, Mullner K, Herszenyi L, Tulassay Z . Update on the pharmacogenomics of proton pump inhibitors. Pharmacogenomics. 2011; 12(6):873-88. DOI: 10.2217/pgs.11.4. View

Marshall B . Helicobacter pylori. Am J Gastroenterol. 1994; 89(8 Suppl):S116-28. View

Hunt R, Cederberg C, Dent J, Halter F, Howden C, Marks I . Optimizing acid suppression for treatment of acid-related diseases. Dig Dis Sci. 1995; 40(2 Suppl):24S-49S. DOI: 10.1007/BF02214870. View

Welage L, Berardi R . Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases. J Am Pharm Assoc (Wash). 2000; 40(1):52-62; quiz 121-3. DOI: 10.1016/s1086-5802(16)31036-1. View

10.

Tuskey A, Peura D . The use of H2 antagonists in treating and preventing NSAID-induced mucosal damage. Arthritis Res Ther. 2013; 15 Suppl 3:S6. PMC: 3890976. DOI: 10.1186/ar4178. View

11.

Barkun A, Bardou M, Marshall J . Consensus recommendations for managing patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med. 2003; 139(10):843-57. DOI: 10.7326/0003-4819-139-10-200311180-00012. View

12.

Kahrilas P, Shaheen N, Vaezi M . American Gastroenterological Association Institute technical review on the management of gastroesophageal reflux disease. Gastroenterology. 2008; 135(4):1392-1413, 1413.e1-5. DOI: 10.1053/j.gastro.2008.08.044. View

13.

Chey W, Inadomi J, Booher A, Sharma V, Fendrick A, Howden C . Primary-care physicians' perceptions and practices on the management of GERD: results of a national survey. Am J Gastroenterol. 2005; 100(6):1237-42. DOI: 10.1111/j.1572-0241.2005.41364.x. View

14.

Khan M, Santana J, Donnellan C, Preston C, Moayyedi P . Medical treatments in the short term management of reflux oesophagitis. Cochrane Database Syst Rev. 2007; (2):CD003244. DOI: 10.1002/14651858.CD003244.pub2. View

15.

Peura D, Kovacs T, Metz D, Siepman N, Pilmer B, Talley N . Lansoprazole in the treatment of functional dyspepsia: two double-blind, randomized, placebo-controlled trials. Am J Med. 2004; 116(11):740-8. DOI: 10.1016/j.amjmed.2004.01.008. View

16.

Laine L, PETERSON W . Bleeding peptic ulcer. N Engl J Med. 1994; 331(11):717-27. DOI: 10.1056/NEJM199409153311107. View

17.

Vigneri S, Termini R, Leandro G, Badalamenti S, Pantalena M, Savarino V . A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med. 1995; 333(17):1106-10. DOI: 10.1056/NEJM199510263331703. View

18.

Stanghellini V, Frisoni C . Editorial: Reflux, dyspepsia, and Rome III (or Rome IV?). Am J Gastroenterol. 2010; 105(12):2632-4. DOI: 10.1038/ajg.2010.354. View

19.

Kaye J, Jick H . Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy. 2008; 28(8):951-9. DOI: 10.1592/phco.28.8.951. View

20.

Gabriel S, Jaakkimainen L, Bombardier C . Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med. 1991; 115(10):787-96. DOI: 10.7326/0003-4819-115-10-787. View